Sign inJoin waitlistJoin the waitlist

Chana Glasser

Division Chief, Pediatric Hematology and Oncology, NYU Langone Hospital- Long Island · NYU Grossman School of Medicine

Credentials: · ·

History

Pediatric Hematology and Oncology Division · NYU Grossman School of Medicine
Present
Hematology-Oncology System · NYU Grossman School of Medicine
Present
NYU Grossman School of Medicine
Present

Pediatric Hematology Oncology
New York Presbyterian Hospital
2014–2015
Pediatrics
Icahn School of Medicine at Mount Sinai
2009–2012
Rutgers University
2005–2009

Research

Characterization of COVID-19 disease in pediatric oncology patients: The New York-New Jersey regional experience
Pediatric Blood & Cancer · 2021 · 90 citations
Everolimus improves the efficacy of dasatinib in PDGFRα-driven glioma
Journal of Clinical Investigation · 2020 · 64 citations
Sirolimus as an Effective Agent in the Treatment of Immune Thrombocytopenia (ITP) and Evans Syndrome (ES): A Single Institution's Experience
Journal of Pediatric Hematology/Oncology · 2017 · Last of 3 authors · 35 citations

JB
Julia Bender
3 papers
MW
Mark Weinblatt
3 papers
AS
Anthony Sireci
2 papers
Birte Wistinghausen
2 papers
JT
Juli Tomaino
2 papers
Lauren Weintraub
2 papers · 1 as a fellow
Lianna Marks
2 papers · 2 as a fellow
Mahesh Mansukhani
2 papers
MS
Maria Sulis
2 papers
Prakash Satwani
2 papers
Susan Hsiao
2 papers
SJ
Sylwia Jasinski
2 papers · 2 as a resident

Clinical trials

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2030
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)
Site PI · Recruiting · Phase 3
Children's Oncology Group
2025–2031
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2024–2029
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2023–2031